Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report


Por: Munarriz, D, López-Godino, O, Martinez-Cibrian, N, Albiol, N, Brillembourg, H, Navarro-Velázquez, S, Español-Rego, M, Casanueva, S, García-Tomás, L, Muñoz-Sanchez, G, Alserawan, L, Benitez-Ribas, D, Magnano, L, Correa, JG, Rivero, A, Mozas, P, Gine, E, Rodríguez-Lobato, LG, Martínez-Roca, A, Montoro-Lorite, M, Ayora, P, Esteve, J, Frutos, L, Balagué-Ponz, O, Urbano-Ispizua, A, González-Navarro, EA, Juan-Otero M, Delgado, J and Ortiz-Maldonado, V

Publicada: 23 sep 2025
Resumen:
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma characterized by a profoundly immunosuppressive tumor microenvironment. PD-L1 overexpression by tumor cells is a recognized immune escape mechanism and may underlie resistance to cellular therapies, including CAR T-cell therapy. We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. Peripheral blood analysis revealed persistent absolute B-cell aplasia, while bone marrow biopsy confirmed CD19-positive disease. Comparative immunohistochemistry demonstrated markedly increased PD-L1 expression in post-CAR T-cell samples, suggesting adaptive immune resistance via PD-1/PD-L1-mediated CAR T-cell inhibition. Nivolumab was initiated at month +4 to overcome this checkpoint-mediated resistance. Notably, a complete metabolic response was documented on PET/CT after four doses of nivolumab (month +6). The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.

Filiaciones:
Munarriz, D:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

López-Godino, O:
 Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Dept Hematol, IMIB Pascual Parrilla, Murcia 30008, Spain

Martinez-Cibrian, N:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

Albiol, N:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

Brillembourg, H:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

Navarro-Velázquez, S:
 Univ Barcelona, Fac Med, Barcelona 08007, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Español-Rego, M:
 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Casanueva, S:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

García-Tomás, L:
 Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Dept Hematol, IMIB Pascual Parrilla, Murcia 30008, Spain

Muñoz-Sanchez, G:
 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Alserawan, L:
 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Benitez-Ribas, D:
 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Magnano, L:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Correa, JG:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

Rivero, A:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

Mozas, P:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Gine, E:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Rodríguez-Lobato, LG:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Martínez-Roca, A:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

Montoro-Lorite, M:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

Ayora, P:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

Esteve, J:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Frutos, L:
 Hosp CU Virgen Arrixaca, Dept Nucl Med, Murcia 30120, Spain

Balagué-Ponz, O:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

 Hosp Clin Barcelona, Dept Pathol, Barcelona 08036, Spain

Urbano-Ispizua, A:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

 Josep Carreras Res Inst, Barcelona 08916, Spain

González-Navarro, EA:
 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Juan-Otero M:
 Univ Barcelona, Fac Med, Barcelona 08007, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona 08036, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

 Clin St Joan Deu Immunotherapy Platform, Barcelona 08036, Spain

Delgado, J:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

Ortiz-Maldonado, V:
 Hosp Clin Barcelona, Dept Hematol, Barcelona 08036, Spain

 Univ Barcelona, Fac Med, Barcelona 08007, Spain

 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain

 Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA 98109 USA
ISSN: 16616596





INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Editorial
MDPI, MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 26 Número: 19
Páginas:
WOS Id: 001593637300001
ID de PubMed: 41096533
imagen Green Submitted, gold

MÉTRICAS